AI Trends

Isomorphic Labs Completes $5 Billion Series C Funding, Setting a New Record for a Single AI Pharma Financing Round

Cailian PressUpdated Nov 18 11:23

AI summary

Isomorphic Labs, the AI drug discovery company under Alphabet, has completed a $5 billion Series C funding round, co-led by Greenoaks and Sequoia Capital, with a16z newly participating and Alphabet continuing to make a large additional investment, setting a new global record for a single AI pharma financing round. The company's CEO is Demis Hassabis, co-founder of DeepMind and winner of the 2024 Nobel Prize in Chemistry. It has developed its own AI drug design engine, IsoDDE, pursuing an end-to-end generative drug R&D route combining large models with intelligent Agents. Currently, the company has no candidate drug in clinical trials; this round of funding will go toward iterating the IsoDDE model, advancing internal proprietary pipelines, and building global infrastructure.

Why read this

AI score 61

Beyond the funding size and the lineup of investors, the original text also notes the context that no candidate drug has yet entered clinical trials, making it easier to gauge the distance between capital's bets and technological progress.

Topics

Tags

Body · AI translation

Cailian Press Financial News Agency

Open the APP

Refreshing the record for a single AI drug discovery financing round! Why is Isomorphic Labs favored by star investors?

STAR Market Daily, Song Ziqiao, Editor: Ji Sheng, 2026-11-18 10:14

① Greenoaks and Sequoia Capital co-led the round, with a16z participating as a new investor, while Alphabet continued to make large additional investments; ② The company's CEO is the 2024 Nobel Prize in Chemistry laureate; ③ The company's self-developed AI drug design engine IsoDDE follows an end-to-end generative drug R&D route of "large models + intelligent Agents."

STAR Market Daily, November 18 (Editor: Song Ziqiao) — On November 17 local time, Isomorphic Labs, an AI drug R&D company under Google parent company Alphabet, officially announced the completion of a $5 billion (approximately RMB 33.3 billion) Series C financing. The round was oversubscribed and set a new record for the scale of a single financing round in the global AI pharmaceutical industry.

The round was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz (a16z) participating as a new investor; Alphabet continued to make large additional investments, and all existing shareholders, including Thrive Capital, MGX, GV, Capital G, Temasek, and the UK Sovereign AI Fund, continued to follow on.

It is worth noting that although it has reached major new drug R&D collaborations with multinational pharmaceutical companies such as Eli Lilly, Novartis, and Johnson & Johnson, Isomorphic Labs currently has no candidate drugs in clinical trials.

Why is a pharmaceutical company whose drugs have not yet been clinically validated favored by so many star investors?

Isomorphic Labs was spun out of Google DeepMind and founded in February 2021. Headquartered in London, with offices in Cambridge and Lausanne, it is an independently operated AI new drug R&D entity within the Alphabet system. Demis Hassabis, co-founder of Google DeepMind, serves as CEO. Hassabis won the 2024 Nobel Prize in Chemistry for research on the AI model AlphaFold2 in protein structure prediction.

Demis Hassabis

The company's President Max Jaderberg also comes from DeepMind. Its core executive team brings together talent in AI basic research, computational biology, medicinal chemistry, and clinical development and commercialization, including Chief Scientific Officer Miles Congreve and Chief Medical Officer Ben Wolf, both senior pharmaceutical R&D leaders. The team is composed of machine learning scientists, structural biologists, medicinal chemists, and translational medicine experts.

In addition, its scientific advisory board brings together multiple Nobel laureates, including CRISPR gene editing pioneer Jennifer Doudna, chemist David MacMillan, as well as Paul Nurse and Venki Ramakrishnan.

Isomorphic Labs' technological foundation originates from the AlphaFold protein structure prediction breakthrough, but it has not stopped at protein structure analysis. It has self-developed the AI drug design engine IsoDDE, following an end-to-end generative drug R&D route of "large models + intelligent Agents."

Unlike most AI pharmaceutical companies that use AI only for single-point auxiliary tasks such as target screening and molecular docking, IsoDDE integrates multiple sets of AI models and can operate natively across multiple therapeutic areas and drug modalities, attempting to precisely simulate biological behavior at the molecular level.

This means that the platform can, with the help of AI agents, autonomously explore vast chemical spaces and simultaneously evaluate molecular druggability, selectivity, and toxicity risks, covering multiple drug modalities such as small molecules and antibodies and spanning multiple therapeutic areas such as oncology and immunology, thereby designing molecules with ideal drug-like properties.

In the latest financing announcement, he said that based on IsoDDE, the R&D team can achieve reproducible scientific progress every week, and these advances directly translate into better molecular characteristics that are expected to become new drugs and to solve some of the most difficult problems in drug R&D.

Looking back at the company's financing history, Isomorphic Labs completed its first external financing round in March 2025, raising $600 million, led by Thrive Capital with participation from Alphabet and GV; in May 2026, the company closed a $2.1 billion Series B financing, which also set a new high for a single financing round in the AI pharmaceutical field at the time, with new sovereign capital and globally renowned growth funds such as Temasek, MGX, and the UK Sovereign AI Fund joining, further expanding its investor lineup.

The $5 billion from this round will be focused on IsoDDE model iteration, discovery of new biological mechanisms, advancement of internal self-developed pipelines, and building a partner ecosystem. At the same time, Isomorphic Labs is building the global infrastructure needed to support the future of AI-driven bioengineering and to advance its drug candidates into clinical trials.

From the industry landscape, technology companies including Google, Microsoft, OpenAI, and Anthropic have all entered the life sciences field; large pharmaceutical companies such as Eli Lilly have chosen to cooperate with AI pharmaceutical companies; and AI biotechnology companies such as Fauna Bio, Blank Bio, and Twist Bio continue to make new progress.

The institution further stated that the "iron triangle" formed by "compute-model-wet lab data" depicts the full landscape of the AI pharmaceutical industry chain: compute forms the foundation of AI drug R&D, vertical models constitute the core of the technology, and wet lab data, as the rate-limiting step, has become the current core of competition. Upstream segments such as life science tools, protein expression, high-throughput validation, and preclinical CRO are expected to be the first to realize the logic and deliver results.

Huaxin Securities stated that currently most of those laying out AI4S are overseas large-model companies, but enterprises in the validation services industry chain with complete Gene-to-Protein capabilities are mainly concentrated in China, and leading companies are actively responding by expanding supporting capacity to take on more overseas orders. AI development is expected to accelerate new drug R&D, driving increased demand for wet lab validation, with orders increasing quarter by quarter.

Artificial Intelligence

AIGC

Cailian Press statement: The content of this article is for reference only and does not constitute investment advice. Investors who act on it do so at their own risk.

Business Cooperation

Popular Unlocks

[Intraday Treasure] A globally strategic must-contest field in technology, industrial R&D has entered a critical window period, and the industry has made significant progress in multiple aspects. This company's mid-to-high-end product sales in the first half of the year increased by more than 150% year on year.

A globally strategic must-contest field in technology, industrial R&D has entered a critical window period, and the industry has made significant progress in multiple aspects. This company's products are key equipment in a niche segment, and its mid-to-high-end product sales in the first half of the year increased by more than 150% year on year.

[Playing with ETFs] The iteration cycle is accelerating, and this field has entered a "predictable and plannable" continuous evolution track. With continued adaptation, it is expected to drive further improvement of the related ecosystem.

① The iteration cycle is accelerating, and this field has entered a "predictable and plannable" continuous evolution track. With continued adaptation, it is expected to drive further improvement of the related ecosystem; ② Industry insiders say that such assets may have certain defensive attributes; ③ Institutions: Looking back at history, the decline and bottoming process after the dot-com bubble.

Related Reading

Anthropic IPO wildly oversubscribed! Silicon Valley investment veteran reveals: oversubscription of 10 to 20 times

Cailian Press Bian Chun 2026-11-18 07:58

① Brad Gerstner, CEO of U.S. technology investment firm Altimeter Capital, revealed that the IPO subscription heat for AI giant Anthropic is extremely high, with oversubscription reaching 10 to 20 times; ② Meanwhile, sources say Anthropic has attracted multiple IPO subscription orders of $10 billion or more.

Dismissing the 50-basis-point expectation? The Fed's "third in command": no aggressive measures needed now, pace of rate hikes depends on AI!

Cailian Press Huang Junzhi 2026-11-18 07:58

① New York Fed President Williams said the current situation does not require drastic action; ② But efforts are still needed to ensure inflation is brought down to around 2% in a timely and sustained manner; ③ How many times and how fast the Fed needs to raise rates will depend on the development of artificial intelligence.

Up 3% after hours! Nvidia's earnings far exceed expectations, board explicitly does not consider reinstating Jensen Huang

Cailian Press Liu Rui 2026-11-18 06:43

① Nvidia disclosed its fiscal 2027 third-quarter earnings, with revenue of $115.84 billion and data center revenue of $107.6 billion, more than doubling year on year; ② The company expects next-quarter revenue to grow about 90% year on year to around $130 billion; ③ Nvidia's board has no intention of reappointing Jensen Huang as chief executive officer.

Source

Cailian Press